Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical
Industries Ltd.

General
Message to
Investors
Management
& Directors
Financial
Data
Products
& Services
News
Videos
Other
Sources

Key Executives:

Dr. Phillip Frost
Chairman

Shlomo Yanai
CEO & President

Investor Relations:

Elana Holzman Phone: +972-3-926-7554

Web Site:

http://www.tevapharm.com

Email:

elana.holzman@teva.co.il

Exchange:

NASDAQ	Symbol: TEVA	Year Listed: 1982
TASE	Symbol: TEVA	Year Listed: 1951

Main Indexes:

TA25, TA100, Maala SRI, NASDAQ Israel, NASDAQ Global Select Market, NASDAQ 100

Industry:

Healthcare, Pharmaceuticals

Year Established:

1901

# of Employees:

47,000

Research Coverage:

Banc of America Merrill Lynch, Bank Hapoalim, Barclays Capital, Buckingham Research, Citi, Clal Finance, Collins Stewart plc, Cowen and Company, LLC, Credit Agricole Securities, Credit Suisse, CRT Capital Group, Deutsche Bank, Exane BNP Paribas, First Global Stockbroking, Gabelli & Company, Goldman Sachs & Co., Harel Finance, IBI Investment House Ltd., J.P. Morgan Securities Inc., Jefferies & Company, Inc., Leader Capital Markets, Needham & Co., Oppenheimer & Co., Piper Jaffray & Co., Psagot Securities, Sanford C. Bernstein, UBS, Wells Fargo Securities

Auditor:

Kesselman & Kesselman (member of PricewaterhouseCoopers)

Law Firm:

Tulchinsky, Stern & Co., Willkie Farr & Gallagher

Main Subsidiaries:

Rating:

Platinum (Rated by Maala CSR)

Office Address:

P.O. Box 3190, Petach Tikva 49131 Israel

Telephone:

+972-3-926-7267

Fax:

+972-3-923-4050

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the leading prescribed treatment for multiple sclerosis. Teva currently employs approximately 47,000 people around the world and reached $18.3 billion in net sales in 2011.

   In 2010, Teva launched 18 generic products in the U.S. and over 300 generic products in European and International markets. Teva boasts the broadest generic product pipeline in the industry. As of July 12, 2011, Teva had 185 product registrations awaiting final FDA approval, including 41 tentative approvals. Collectively, the branded products covered by these applications had annual U.S. sales of over $116 billion in 2010. Of these applications, 126 were "Paragraph IV" applications challenging patents of branded products. Teva believes it is the first to file on 77 of the applications, relating to products with annual U.S. branded sales exceeding $54 billion. As of June 30, 2011, Teva had 2,927 marketing authorization applications pending approval in 30 European countries, relating to 301 compounds in 589 formulations, including 10 applications pending with the EMA.
   Following the acquisition of ratiopharm in August 2010, Teva became the generics leader in Europe and increased its presence in key markets.
   In November 2011, Teva and The Procter & Gamble Company created a global partnership in over-the-counter (OTC) medicines. This new business model combines P&G's strong brand-building, consumer-led innovation and go-to-market capabilities with Teva's broad geographic reach, its experience in R&D, regulatory and manufacturing and its extensive portfolio of products.

In October 2011, Teva completed the acquisition of Cephalon for $6.5 billion. The transaction reinforces Teva’s long-term strategy of building its branded and specialty pharmaceuticals business through diversification and expansion of the company’s product portfolio and pipeline. The combined company’s branded portfolio represents $7 billion in sales, with a robust pipeline including more than 30 late-stage compounds. The transaction will create immediate and sustainable value in niche therapeutic areas including CNS, oncology, respiratory and pain management. The combined company will become a leader in specialty pharma.

In September 2011, Teva agreed to acquire the remaining 50% interest held by Kowa Company Ltd. in Teva's Japanese joint venture for $150 million. Teva and Kowa announced the establishment of Teva-Kowa Pharma Co., Ltd. in September 2008, and have since grown the joint venture into one of the top five generic players in Japan, in cooperation with Kowa. The joint venture generated sales of approximately $200 million in 2010.

In July 2011, Teva completed the acquisition of effectively 100% of the outstanding shares of Taiyo Pharmaceutical Industry Co. Ltd. for $934 million in cash. Taiyo is the third largest generic pharmaceutical company in Japan, with sales of $530 million in 2010. This acquisition will enable Teva to deliver on its strategic objective of becoming a leading player in the fast-growing Japanese generics market. Following the acquisition, Teva expects to reach $1 billion in sales in Japan, ahead of its original 2015 target.
In January 2011, Teva acquired Corporacion Infarmasa, a top ten pharmaceutical company in Peru, expanding the company's Latin American activity and advancing its position as a market leader in the region. It also completed the acquisition of Theramex, a European-based women's health business. The acquisition will help accelerate the expansion of Teva's women’s health franchise into key growth markets in Europe and around the world. In July 2011, Teva received a European marketing authorization for Zoely™, an innovative combined oral contraceptive (COC) which contains a natural estrogen. Zoely™ is available in a convenient 24 day active and 4 day placebo dosing regimen. Teva holds exclusive marketing rights for ZOELY™ in France, Italy, Belgium and Spain and expects the first launch by the end of the year.

Management

CEO & President: Shlomo Yanai

Shlomo Yanai has been the President and Chief Executive Officer of Teva since March 2007. Prior to joining Teva, Mr. Yanai was President and Chief Executive Officer of Makhteshim-Agan Industries Ltd. from 2003 until 2006. Previously, Mr. Yanai served in the Israel Defense Forces (the "IDF") for 32 years, where he achieved the rank of Major General, the highest rank below Chief of Staff, and successively held two of the most senior positions: Commanding Officer of the Southern Command and Head of the Division of Strategic Planning. Mr. Yanai was the head of the Israeli security delegation to the peace talks at Camp David, Shepherdstown and Wye River. Mr. Yanai was a board member of Bank Leumi Le-Israel Ltd. from 2004 until 2007. Mr. Yanai is a member of the Board of Governors of the Technion (Israel Institute of Technology) and of the International Advisory Board, M.B.A. Program of Ben-Gurion University of the Negev, as well as an honorary member of the Board of the Institute for Policy and Strategy of the Interdisciplinary Center (IDC) Herzliya. Mr. Yanai received a B.A. in political science and economics from Tel Aviv University in 1983 and an M.P.A. in national resources management from George Washington University in 1990, and graduated the Advanced Management Program of the Harvard Business School in 2000.

CFO: Eyal Desheh

Eyal Desheh became Chief Financial Officer in July 2008. Mr. Desheh had previously served as Deputy Chief Financial Officer at Teva from 1989 to 1996. From 2000 until 2008, he was Executive Vice President and Chief Financial Officer of Check Point Software Technologies Ltd. Mr. Desheh received a B.A. in economics in 1978 and an M.B.A. in finance in 1981, both from the Hebrew University.

Directors

Chairman: Dr. Phillip Frost

Dr. Philip Frost has served as Chairman of the Board of Teva since March 2010, after serving as Vice Chairman of the Board since January 2006 and as Chairman of the Board and Chief Executive Officer of IVAX Corporation from 1987 until 2006. He was also President of IVAX from 1991 until 1995. Dr. Frost is Chairman of the Board and CEO of OPKO Health, Inc., a specialty pharmaceutical company, Chairman of the Board of PROLOR Biotech Inc. and Chairman of the Board of Ladenburg Thalmann Financial Services. Dr. Frost serves as a director of Continucare Corporation Inc. and Castle Brands Inc. He is also a member of the Board of Trustees of The Scripps Research Institute and of the Board of Trustees of the University of Miami. Dr. Frost received a B.A. in French literature from the University of Pennsylvania in 1957 and an M.D. from the Albert Einstein College of Medicine in 1961.

Vice Chairman: Prof. Moshe Mani

Prof. Moshe Many, M.D., Ph.D. has served as Vice Chairman of the Board of Teva since March 2010, having been a director of Teva since 1987. Prof. Many has served as president of the Ashkelon Academic College since January 2002 and was previously President of Tel Aviv University. He served as Chief of Urology from 1976 until 1987 and Chairman of Surgery from 1983 until 1987 at Sheba Medical Center. Prof. Many serves as Chairman of the Board of Real Imaging Ltd. and a director of BiondVax Pharmaceuticals Ltd. and of Rosetta Genomics Ltd. In January 2010, he received the Israel Ministry of Health Lifetime Achievement Award in recognition of his outstanding and unique contributions to the promotion and support of health matters in Israel. Prof. Many received his M.D. degree from Geneva University in 1952 and his Ph.D. in renal physiology from Tufts University in 1969.

Roger Abravanel

Roger Abravanel has been a director of Teva since 2007. In 2006 Mr. Abravanel retired from McKinsey & Company, which he joined in 1972 and where he had become a principal in 1979 and a director in 1984. Mr. Abravanel serves as a director of Luxottica Group S.p.A., and the Italian Institute of Technology. Mr. Abravanel received a bachelor's degree in chemical engineering from the Politechnic University in Milan in 1968 and an M.B.A. from INSEAD in 1972.

Ruth Cheshin

Ruth Cheshin has been a director of Teva since 1989. She is the President of the Jerusalem Foundation, a multi-national organization headquartered in Jerusalem, invested in advancing a pluralistic and modern society in Jerusalem through social, educational, cultural and coexistence projects for all citizens of Jerusalem. Ms. Cheshin is also an active member of many of the city's most important boards. Ms. Cheshin is the aunt of Chaim Hurvitz.

Abraham E. Cohen

Abraham E. Cohen has been a director of Teva since 1992. He was Senior Vice President of Merck & Co. from 1982 to 1992 and served as President of the Merck Sharp & Dohme International Division from 1977 to 1988. Since his retirement from Merck in January 1992, Mr. Cohen has been active as an international business consultant. He served as a director of Akzo Nobel NV until 2007. He is presently a director of Chugai Pharmaceutical Co., Ltd., BioTime, Inc. and Mannkind Corporation.

Amir Elstein

Amir Elstein rejoined Teva's Board in January 2009. From 2004 to 2008, Mr. Elstein was a member of Teva's senior management, where most recently he held the position of Executive Vice President, Global Pharmaceutical Resources. From 1995 to 2004, Mr. Elstein served on the Company's Board of Directors. Prior to joining Teva in 2004, Mr. Elstein held a number of executive positions at Intel Corporation, most recently as General Manager of Intel Electronics Ltd., an Israeli subsidiary of Intel Corporation. Mr. Elstein serves as Chairman of the Board of Israel Corporation Ltd, Chairman of the Board of Tower Semiconductor Ltd, and Chairman of the Board of Governors of the Jerusalem College of Engineering. Mr. Elstein received a B.Sc. in physics and mathematics from the Hebrew University in Jerusalem in 1980, an M.Sc. in solid state physics from the Hebrew University in 1982 and a diploma of Senior Business Management from the Hebrew University in 1992.

Chaim Hurvitz

Chaim Hurvitz joined Teva's Board in October 2010. Previously, he was a member of Teva's senior management, serving as the President of Teva International Group from 2002 until 2010, as President and CEO of Teva Pharmaceuticals Europe from 1992 to 1999 and as Vice President-Israeli Pharmaceutical Sales from 1999 until l 2002. He received a B.A. in political science and economics from Tel Aviv University in 1985. Mr. Hurvitz is the nephew of Ms. Cheshin.

Elon Kohlberg

Prof. Elon Kohlberg has been a director of Teva since 2009. He is the Royal Little Professor of Business Administration at the Harvard Business School, where he has taught since 1973. Prof. Kohlberg previously served on Teva's Board from 1987 to 2000. Between 2005 and 2007, Prof. Kohlberg served as director of Ormat Technologies, Inc. Prof. Kohlberg received a B.Sc. (1966), M.Sc. (1967), and Ph.D. (1973) in mathematics from the Hebrew University of Jerusalem.

Prof. Roger Kornberg

Prof. Roger D. Kornberg has been a director of Teva since 2007. He is the Winzer Professor in Medicine in the Department of Structural Biology at Stanford University, where he has taught since 1978. Prof. Kornberg received a B.A. in chemistry from Harvard in 1967 and a Ph.D. in chemistry from Stanford in 1972. He has received many awards, including the Welch Prize (2001), the highest award in chemistry in the U.S., the Leopold Mayer Prize (2002), the highest award in biomedical sciences of the French Academy of Sciences, and the Nobel Prize in Chemistry (2006). He is a recipient of honorary degrees from universities in Europe and Israel, including the Hebrew University, where he is a visiting professor. He is a member of the National Academy of Sciences and an honorary member of other academies and professional societies in the U.S., Europe and Japan. Prof. Kornberg has served since 2008 as a director of Protalix BioTherapeutics.

Dr. Leora Meridor

Dr. Leora (Rubin) Meridor has been a director of Teva since 2002. Dr. Meridor is a business and financial consultant. She served as the Chair of the Board of Bezeq International Ltd. and Walla Communications Ltd. from 2001 to 2005 and as Chair of the Board of Hapoalim Capital Markets from 2001 to 2004. From 1996 to 2000, Dr. Meridor was Senior Vice President and Head of the Credit and Risk Management Division of the First International Bank of Israel. Dr. Meridor received a B.Sc. in 1970 in mathematics and physics, an M.Sc. in 1972 in mathematics and a Ph.D. in economics from the Hebrew University, where she has held various teaching positions. She served as director of NICE Systems Ltd. from 2002 until 2007 and of Isrotel Ltd. from 2001 until 2007. She presently serves as director of Alrov (Israel) Ltd., Gilat Satellite Networks Ltd. and Osem Investment Ltd. Dr. Meridor qualifies as a statutory independent director under Israeli law and was determined by the Board to be a financial and accounting expert under Israeli law.

Joseph Nitzani

Joseph Nitzani has been a director of Teva since 2008. Between 2001 and 2007, Mr. Nitzani held various management positions at Mizrahi-Tefachot Bank Ltd., most recently as Head of the Capital Markets Division. Previously, he served as Managing Director of The Government Companies Authority from 1991 to 1995 and CEO of The Tel-Aviv Stock Exchange from 1980 to 1991. He has served as a director in three subsidiaries of Migdal Capital Markets Group since December 2009 (and as a Chairman of one of them since 2010). He also served as a director of Adanim Mortgage Bank from 2006 to 2008 and of Hadassah Medical Center from 1996 (as Chairman since June 2008) to 2010. Mr. Nitzani received a B.A. in economics from Bar-Ilan University in 1971 and an M.B.A. (with distinction) from Tel Aviv University in 1974. Mr. Nitzani qualifies as a statutory independent director under Israeli law and was determined by the Board to be a financial and accounting expert under Israeli law.

Uri Slonim

Ory Slonim rejoined Teva's Board in June 2008. Mr. Slonim is an attorney who has been in private practice since 1970 and previously served on Teva's Board from 1998 to 2003 as a statutory independent director. Between 1987 and 2007, Mr. Slonim was a director at Migdal Insurance Company Ltd., serving as deputy chairman from 2000 until 2007 and as chairman of the company's audit committee from 2001 until 2007. He presently serves as a director and chairman of the audit committee of U. Dori Group Ltd., director and chairman of the audit committee of Oil Refineries Ltd. and as vice chairman of Harel Insurance Investments & Financial Services Ltd. Mr. Slonim has served as Chairman of Variety Club in Israel since 2006. Mr. Slonim received an LL.B degree from the Hebrew University in 1968.

Dan S. Suesskind

Dan S. Suesskind joined Teva's Board in January 2010. He was Teva's Chief Financial Officer from 1977 until 2008. He previously served as a director of Teva from 1981 to 2001. Currently, Mr. Suesskind serves as a director of several companies, including Migdal Insurance Company Ltd., Ness Technologies Inc. and Syneron Medical Ltd., as well as a member of the board (and finance and investment committee) of the Jerusalem Foundation, a member of the Investment Committee of the Israel Academy of Science and Humanities and the Board of Trustees of the Hebrew University. He is one of the founders and a member of the steering committee of the Israeli Forum of Chief Financial Officers. He received a B.A. in economics and political science from the Hebrew University in 1965 and an M.B.A. from the University of Massachusetts in 1969.

Erez Vigodman

Erez Vigodman has been a director of Teva since 2009. Since January 2010, he has been President and Chief Executive Officer of Makhteshim Agan From 2001 through June 2009, Mr. Vigodman served as President and Chief Executive Officer of Strauss Group Ltd. Mr. Vigodman is a member of the Advisory Committee to the Israel National Economic Council. He received a B.A. in accounting and economics from Tel Aviv University in 1987 and is a graduate of the program of Management Development at Harvard Graduate School of Business Administration. Mr. Vigodman is a certified public accountant.

	Three Months Ended December 31
Income Statement Data ($m)	2011	2010
Total Revenues	5,676	4,418
Gross Profit	3,443	2,464
Gross Margins %	61%	56%
Operating Income	1,732	774
Finance Expenses, Net	68	47
Net Income	1,407	1,141
Diluted Earnings Per Share ($)	1.59	1.25
*all figures are non-GAAP

	Year Ended December 31
Income Statement Data ($m)*	2011	2010	2009
Total Revenues	18,312	16,121	13,899
Gross Profit	10,705	9,669	8,119
Gross Margins %	58%	60%	58%
Operating Income	5,253	4,933	3,853
Finance Expenses, Net	153	225	202
Net Income	4,438	4,134	3,029
Diluted Earnings Per Share ($)	4.97	4.54	3.37
*all figures are non-GAAP

Balance Sheet Data ($m)	12/31/11	12/31/10
Total Cash & ST Investments	1,096	1,248
Current Assets	14,453	12,042
Total Assets	50,142	38,152
Current Liabilities	13,847	9,694
Total Equity	22,343	22,002

Key Financial Ratios	12/31/11	12/31/10
Current Ratio	1.0x	1.2x
L-T Debt/Equity	45.8%	18.7%

Business Summary	2011
	Revenues
US	48%
Europe*	31%
ROW	21%
*includes EU member states, Switzerland and Norway.

Dividend Policy

Company pays regular quarterly dividends.

Main Shareholders (Februray 16, 2012)

No shareholder holds more than 5%.

Branded Products

Copaxone
Copaxone (glatiramer acetate injection, or GA), our largest product and first major innovative drug, is the leading multiple sclerosis therapy in the U.S. and globally and is approved in over 50 countries worldwide, including the U.S., Canada, all European countries, Russia, major Latin American markets, Australia and Israel. It is indicated for reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Copaxone is also indicated for the treatment of patients who have experienced clinically isolated syndrome and are determined to be at high risk of developing clinically definite multiple sclerosis.

More Info

Azilect
Azilect (rasagiline tablets), indicated for the treatment of Parkinson’s disease as initial monotherapy and as an adjunct to levodopa, is our second innovative drug to be in the market. Parkinson’s disease is the second most common neurodegenerative disorder, which typically occurs at an advanced age, affecting approximately 1-2% of the population over the age of 65 and increasing to 3-5% in people over the age of 85. Although many symptomatic therapies are available, there is still a high level of dissatisfaction with many of these treatments, in terms of efficacy, safety and tolerability. The major unmet need for Parkinson’s disease is to slow the clinical progression of the disease.

More Info

ProAir
ProAir (albuterol HFA) is a short-acting betaagonist for treatment of bronchial spasms linked to asthma or COPD and exercise-induced bronchospasm. ProAir is marketed directly to physicians, pharmacies, hospitals, managed healthcare organizations and government agencies. In 2010, ProAir maintained its position as the leading rescue inhaler in the U.S.

Announcements

14/2/2012
Teva Reports Fourth Quarter and Full Year 2011 Results More Info

16/1/2012
Teva to Report Fourth Quarter and Full Year 2011 Financial Results on February 15, 2012 More Info

9/1/2012
Teva to Present at the 30th Annual J.P. Morgan Healthcare Conference More Info

3/1/2012
Advanced Magnetic Resonance Imaging Technology Suggests Axonal Repair in Multiple Sclerosis Patients Treated with COPAXONE® More Info

1/1/2012
Teva Announces Management Succession More Info

22/12/2011
Dr. Rob Koremans to succeed Dr. Gerard van Odijk as President and CEO of Teva Europe More Info

21/12/2011
Teva Provides 2012 Non-GAAP Financial Outlook; 2012 Non-GAAP Diluted EPS of $5.48 to $5.68 More Info

21/12/2011
Teva Announces $3 billion Share Repurchase Program More Info

13/12/2011
Teva to Host 2012 Business Outlook Conference Call More Info

7/12/2011
Teva Pharmaceuticals Issues Statement on a Statement by U.S. Department of Health and Human Services Secretary Kathleen Sebelius More Info

All Announcements

News

Globes - 19/2/2012 - Teva tempers Laquinimod prognosis
"We believe it would be premature to file an NDA for Laquinimod at this time," the company said in its annual financial report. More Info

Globes - 16/2/2012 - Deutsche Bank more conservative on Teva than Merrill Lynch
Merrill Lynch and Deutsche Bank are both satisfied with Teva's financial report for the fourth quarter and full year of 2011. More Info

Globes - 15/2/2012 - Wed: Teva boosts market
Teva, NICE Systems and Given Imaging rose on positive 2011 financials. More Info

Seeking Alpha - 15/2/2012 - Teva Pharmaceutical's CEO Discusses Q4 2011 Results - Earnings Call Transcript
More Info

Globes - 15/2/2012 - Analysts upbeat on Teva results
Leader and Bank Hapoalim both reiterate "Outperform" recommendations for Teva after it published its financial report today. More Info

Seeking Alpha - 15/2/2012 - Teva Pharmaceuticals: An Even Stronger Buy After Earnings
More Info

Seeking Alpha - 15/2/2012 - With New Management, Teva Seeks To Reclaim Past Glories
More Info

Globes - 15/2/2012 - FDA approves Teva, BioSante testosterone gel
Teva will market BioSante's Bio-T-Gel as a testosterone replacement therapy for men. More Info

Globes - 15/2/2012 - Teva meets analysts' consensus
The pharmaceutical giant reported a 23% rise in profit for the fourth quarter and a 7% rise in profit for full year 2011. More Info

Globes - 14/2/2012 - Teva-Gamida Cell complete enrollment for blood cancer trial
Gamida Cell's StemEx is a cell therapy for the treatment of leukemia and lymphoma for patients who cannot find a matched bone marrow donor. More Info

Teva Financial News

Q4 and YE 2011 Results

Teva Acquisition News

Teva to Acquire Cephalon

Investor Call to Discuss the Acquisition of Cephalon

Presentation: Teva's Acquitision of Cephalon

Morningstar Profile Report

Analyst Research & Recommendations

Market Data: Company Profile

Market Data: At a Glance

Market Snapshot

Summary Share Information

Google Finance
Company Summary

SEC Filings
EDGAR System

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) ist ein führendes, globales Arzneimittelunternehmen, das sich für eine qualitativ hochwertige Gesundheitsversorgung einsetzt, indem es erschwingliche Generika sowie innovative und spezielle Arzneimittel und aktive pharmazeutische Wirkstoffe entwickelt, herstellt und vertreibt. Mit seinem Hauptsitz in Israel handelt es sich bei Teva um den weltweit größten Produzenten von Generika mit einem globalen Produktportfolio von mehr als 1.300 Substanzen und direkter Aktivität in etwa 60 Ländern. Tevas Markengeschäft legt sein Hauptaugenmerk auf die Therapie von neurologischen Beschwerden und Atemwegserkrankungen sowie die weibliche Gesundheit und Biologie. Tevas führendes innovatives Produkt, Copaxone®, ist das am meisten verschriebene Medikament für Multiple Sklerose. Teva hat momentan etwa 45.000 Mitarbeiter weltweit und erreichte 2010 einen Nettoumsatz von $ 16,1 Milliarden.
2010 hat Teva 18 Generika auf dem US-Markt und über 300 Generika auf dem europäischen und internationalen Markt eingeführt. Teva verfügt über die breiteste Produktpalette an Generika der Branche. Mit Stand vom 12. Juli 2011 besaß Teva 185 Produktregistrierungen, die nur noch auf die finale FDA-Zulassung warteten, darunter 41 vorläufige Zulassungen. Gemeinsam erreichten die Markenprodukte, die von diesen Anträgen abgedeckt wurden, 2010 in den USA einen jährlichen Umsatz von $ 116 Milliarden. Von diesen Anträgen waren 126 „Paragraph-IV"-Anträge, die die Patente von Markenprodukten herausforderten. Teva glaubt, dass 77 dieser Anträge zuerst hinterlegt wurden und in Bezug darauf der jährliche US-Markenumsatz $ 54 Milliarden übersteigt. Am 30. Juni 2011 unterhielt Teva 2.927 Vertriebsgenehmigungsanträge in 30 europäischen Ländern, deren Zulassung noch ausstand. Dazu gehören 301 Präparate in 589 Zusammensetzungen mit 10 schwebenden Anträgen bei der EMA.
Nach dem Erwerb von ratiopharm im August 2010 wurde Teva der europäische Marktführer im Bereich Generika und hat seine Präsenz auf den wichtigsten Märkten erhöht.
Im Juli 2011 hat Teva den Kauf von effektiv 100% der ausstehenden Anteile von Taiyo Pharmaceutical Industry Co. Ltd. für $ 934 Millionen in bar abgeschlossen. Bei Taiyo handelt es sich mit einem Umsatz von $ 530 Millionen im Jahr 2010 um das drittgrößte Generika-Arzneimittelunternehmen in Japan. Mit diesem Kauf kann Teva sein strategisches Ziel, Markführer auf dem rasant wachsenden japanischen Markt zu werden, erfüllen. Nach diesem Kauf erwartet Teva einen Umsatz von $ 1 Milliarde in Japan, weit mehr als das ursprüngliche Ziel von 2015.
Im Mai 2011 stimmte Teva zu, Cephalon für $ 6,8 Milliarden zu erwerben. Diese Transaktion untermauert Tevas langfristige Strategie, das Marken- und Spezialgeschäft mit seinen Arzneimitteln durch Vielfalt und die Expandierung des Produktportfolios und der Produktpalette zu stärken. Das kombinierte Markenportfolio des Unternehmens spiegelt sich in $ 7 Milliarden Umsatz wider und verfügt über eine robuste Produktpalette mit mehr als 30 Zusammensetzungen in der späten Entwicklungsphase. Die Transaktion sorgt für eine sofortige und nachhaltige Wertsteigerung in Nischentherapien, darunter ZNS, Onkologie, Atemwegserkrankungen und Schmerztherapie. Diese zusammengeschlossene Firma wird führend im Bereich Spezialarzneimittel sein. Die Transaktion wird voraussichtlich im Oktober 2011 abgeschlossen sein,
Im März 2011 unterzeichneten Teva und das Unternehmen Procter & Gamble eine Vereinbarung über eine globale Partnerschaft für rezeptfreie Medikamente. Dieses neue Geschäftsmodell vereint die starke Markenbildung, die Kundenorientierung und den Go-to-Market-Ansatz von P&G mit der geographischen Reichweite, der Erfahrung in der Forschung, Entwicklung, Regulation und Verwaltung sowie dem breiten Portfolio an Produkten von Teva.
Im Januar 2011 erwarb Teva die Corporacion Infarmasa, eine der top Zehn Arzneimittelfirmen in Peru, womit die Unternehmensaktivitäten bis nach Lateinamerika ausgeweitet und die Position als Marktführer in der Region ausgebaut wurde. Außerdem wurde der Kauf von Theramex, einer Firma mit Sitz in Europa, die sich auf die Gesundheit von Frauen spezialisiert hat, abgeschlossen. Dieser Kauf trägt zur schnelleren Expandierung von Tevas Bereich Frauengesundheit in wichtigen Wachstumsmärkten in Europa und auf der ganzen Welt bei. Im Juli 2011 erhielt Teva eine Vertriebsgenehmigung in Europa für Zoely™, ein innovatives, kombiniertes orales Verhütungsmittel, das ein natürliches Östrogen beinhaltet. Zoely™ ist als praktische 24-Tage-aktiv-Anwendung und 4-Tage-Placebo-Dosierung verfügbar. Teva unterhält die Alleinvertriebsrechte für ZOELY™ in Frankreich, Italien, Belgien und Spanien und erwartet die erste Markteinführung Ende des Jahres.

Teva Pharmaceutical Industries Ltd (NASDAQ : TEVA) est une société pharmaceutique de premier ordre mondial, engagée à accroître l'accès à des soins de qualité en développant, produisant et commercialisant des médicaments génériques abordables ainsi que des produits pharmaceutiques novateurs et spécialisés et des principes pharmaceutiques actifs. Basée en Israël, Teva est le plus grand fabricant mondial de médicaments génériques, avec un portefeuille global de produits de plus de 1 300 molécules et une présence directe dans 60 pays environ. Les entreprises de la marque Teva se concentrent sur les domaines de la thérapeutique neurologique, respiratoire et féminine ainsi que sur celui des produits biologiques. Le produit phare innovant de Teva, le Copaxone ®, est le principal traitement prescrit pour la sclérose en plaques. Teva emploie actuellement environ 45 000 personnes dans le monde et a atteint 16,1 milliards de dollars de ventes nettes en 2010.
   En 2010, Teva lancça 18 produits génériques aux États-Unis et plus de 300 produits génériques sur les marchés européen et international. Teva possède le pipeline le plus large de produits génériques dans l'industrie. Le 12 juillet 2011, Teva détenait 185 enregistrements de produits en attente de l'approbation finale de la FDA, l’o rganisme gouvernemental de contrôle pharmaceutique et alimentaire, dont 41 approbations provisoires. Collectivement, les produits de la marque visés par ces demandes atteignirent des ventes annuelles aux États-Unis équivalant à plus de 116 milliards de dollars 2010. Parmi ces demandes, 126 étaient des applications «Paragraphe IV" contestant des brevets de produits de marque. Teva estime être le premier à avoir déposé un brevet sur 77 des applications, liées à des produits dont les ventes annuelles de marque des États-Unis dépassent la somme de 54 milliards de dollars. Le 30 juin 2011, Teva avait 2 927 demandes d'autorisation de commercialisation en attente d'approbation dans 30 pays européens, portant le nombre de composés dans les formulations à 301 589, dont 10 demandes en instance avec l'EMA, l’association de la commercialisation européenne.
   Suite à l'acquisition de ratiopharm en août 2010, Teva est devenu le leader des médicaments génériques en Europe et a accru sa présence dans des marchés clés.
En juillet 2011, Teva finalisa avec réussite l'acquisition à 100% des actions en circulation de Taiyo Pharmaceutical Industry Co. Ltd. pour un montant de 934 millions de dollars en cash. Taiyo est la troisième société de produits pharmaceutiques génériques la plus grande au Japon, avec des ventes atteignant 530 millions de dollars en 2010. Cette acquisition permettra à Teva de réaliser son objectif stratégique consistant à devenir un acteur majeur dans la croissance rapide du marché des génériques japonais. Suite à l'acquisition, Teva prévoit d'atteindre 1 milliard de dollars de ventes au Japon, davantage que son but préalablement établi pour l’année 2015.
   En mai 2011, Teva décida d'acquérir Cephalon pour la somme de 6,8 milliards de dollars. La transaction renforce la stratégie à long terme de Teva consistant à construire son commerce de pharmaceutiques de marque et de spécialité, grâce à la diversification et à l'expansion du portefeuille de produits et du pipeline de distribution de la société. Le portefeuille combiné de marques de la société représente 7 milliards de dollars en ventes, avec un solide pipeline de distribution dont plus de 30 installations à un stade avancé. La transaction créera de la valeur immédiate et durable au niveau de certains créneaux thérapeutiques incluant le système nerveux central, l’oncologie, la pneumologie et la gestion de la douleur. La société en partenariat deviendra un leader dans les spécialités pharmaceutiques. La transaction devrait être achevée en octobre 2011.
   En mars 2011, Teva signa avec la société Procter & Gamble accord afin de créer un partenariat global dans le domaine des médicaments vendus sans ordonnance. Cette nouvelle structure d'affaires combine la construction d’une marque puissante, une innovation basée sur les consommateurs et des capacités de lancement sur le marché de P & G avec la grande portée géographique, l’expérience en termes de recherche et développement, de législation et de production de Teva, ainsi qu’avec son vaste éventail de produits.
En janvier 2011, Teva acquit la Corporacion Infarmasa, une société pharmaceutique classée parmi les dix plus grandes du Pérou, étendant ainsi les activités en Amérique latine de l'entreprise et l’amenant en position de leader du marché dans la région. Teva acquit également la société européenne Théramex, spécialisée dans la santé des femmes. L'acquisition permettra d'accélérer l'expansion de la franchise de Teva concernant la santé des femmes sur les marchés clés de la croissance en Europe et ailleurs dans le monde. En juillet 2011, Teva reçut une autorisation de commercialisation européenne pour le produit Zoely ™, un programme novateur de contraceptifs oraux combinés (COC) contenant un œstrogène naturel. Zoely ™ est disponible dans un format pratique de 24 jours actifs et 4 jours placebo. Teva détient les droits exclusifs de commercialisation pour ZOELY ™ en France, en Italie, en Belgique et en Espagne et espère effectuer le premier lancement d'ici la fin de l'année.

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) es una empresa farmacéutica global líder, comprometida con un mayor acceso al cuidado de la salud de alta calidad mediante el desarrollo, producción y comercialización de medicamentos genéricos asequibles, junto con fármacos innovadores y especializados e ingredientes farmacológicos activos. Con sede en Israel, Teva es el mayor fabricante de medicamentos genéricos del mundo, con una cartera de productos global de más de 1.300 moléculas y presencia directa en unos 60 países. Los productos de marca de Teva se centran en las áreas neurológicas, respiratorias y terapia de salud femenina junto con la biología. El innovador producto estrella de Teva, Copaxone®, es el tratamiento recetado más importante para la esclerosis múltiple. Teva emplea actualmente a aproximadamente 45.000 personas en todo el mundo y alcanzó los 16.100 millones de dólares en ventas netas en 2010.
En 2010, Teva lanzó 18 productos genéricos en EE.UU. y más de 300 productos genéricos en los mercados europeo e internacional. Teva presume de tener la mayor distribución de producto genérico de la industria. A 12 de julio de 2011, Teva tenía 185 registros de productos esperando la aprobación final de la FDA, incluyendo 41 aprobaciones provisionales. En su conjunto, los productos de marca cubiertos por estas aplicaciones tuvieron unas ventas anuales en EE.UU. de más de 116.000 millones de dólares en 2010. De estas aplicaciones, 126 fueron aplicaciones de “Párrafo IV”, desafiando a patentes de productos de marca. Teva cree que es la primera en presentar 77 de las aplicaciones, relativas a productos con unas ventas de marca anuales en EE.UU. de más de 54.000 millones de dólares. A 30 de junio de 2011, Teva tenía 2.927 aplicaciones con autorización de comercialización pendiente de aprobación en 30 países europeos, relativas a 301 componentes en 589 fórmulas, incluyendo 10 aplicaciones pendientes con la EMA (Agencia de medicamentos europea).
Tras la adquisición de Ratiopharm en agosto de 2010, Teva se convirtió en la empresa de genéricos líder en Europa e incrementó su presencia en mercados clave.
En julio de 2011, Teva completó la adquisición del 100% efectivo de las acciones pendientes de Taiyo Pharmaceutical Industry Co. Ltd. por 934 millones de dólares en efectivo. Taiyo es la tercera mayor compañía de fármacos genéricos de Japón, con ventas de 530 millones de dólares en 2010. Esta adquisición permitirá a Teva cumplir su objetivo estratégico de convertirse en una empresa puntera en el rápidamente creciente mercado de genéricos japonés. Tras la adquisición, Teva espera alcanzar los 1.000 millones de dólares de ventas en Japón, por encima de su objetivo original para 2015.
En mayo de 2011, Teva acordó adquirir Cephalon por 6.800 millones de dólares. La transacción refuerza la estrategia a largo plazo de Teva de construir su negocio de fármacos especializados y de marca a través de la diversificación y expansión de la cartera de productos y de la red de distribución de la compañía. La cartera de marca conjunta de la compañía representa 7.000 millones de dólares en ventas, con una sólida red de distribución que incluye más de 30 compuestos en fase final. La transacción creará un valor inmediato y sostenible en áreas terapéuticas nicho, incluyendo CNS (sistema nervioso central), oncología, aparato respiratorio y cuidados paliativos. La compañía conjunta se convertirá en líder en fármacos especializados. Se espera que la transacción sea completada en octubre de 2011.
En marzo de 2011, Teva y The Procter & Gamble Company firmaron un acuerdo para crear una asociación global en medicinas sin receta (OTC). Este nuevo modelo de negocio combina la gran fuerza de marca de P&G, su innovación hacia el consumidor y su capacidad de entrar en el mercado con el gran alcance geográfico de Teva, su experiencia en I+D, regulaciones y fabricación, y su extensa cartera de productos.
En enero de 2011, Teva adquirió Corporacion Infarmasa, una empresa farmacéutica entre las diez primeras de Perú, expandiendo la actividad latinoamericana de la compañía, y avanzando en su posición como líder del mercado en la región. También completó la adquisición de Theramex, un negocio de salud femenina con sede en Europa. La adquisición ayudará a acelerar la expansión de la franquicia de salud femenina de Teva en importantes mercados de Europa y en todo el mundo. En julio de 2011, Teva recibió una autorización de comercialización europea para Zoely™, un innovador contraceptivo oral combinado (COC) que contiene un estrógeno natural. Zoely™ está disponible en un cómodo régimen de dosificación de activos durante 24 días y placebo durante 4 días. Teva posee derechos de comercialización exclusivos para ZOELY™ en Francia, Italia, Bélgica y España, y espera el primer lanzamiento a finales de año.

language:

Teva Pharmaceutical Industries Ltd. announcements